{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059667","form_type":"8-K","ticker":null,"cik":"0001651407","company_name":"Checkpoint Therapeutics, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.434470+00:00","generated_at":"2026-06-02T03:49:54.217338+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Checkpoint Therapeutics reports Q1 results; cosibelimab BLA resubmission targeted for mid-2024","bullets":["Cash and equivalents $11.2M at March 31, 2024, up from $4.9M at Dec 31, 2023 after $14.0M offering.","Net loss $10.9M ($0.33/sh) vs $10.5M ($0.89/sh) in Q1 2023; R&D expenses fell to $8.5M from $15.8M.","Third-party CMO submitted response to FDA inspection deficiencies from Dec 2023 CRL; company plans FDA meeting for mid-year BLA resubmission.","Board appointed Dr. Amit Sharma, VP at Alexion/AstraZeneca, as non-executive director in March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059667","json":"https://secwatch.observer/filing/0001104659-24-059667.json","markdown":"https://secwatch.observer/filing/0001104659-24-059667.md","text":"https://secwatch.observer/filing/0001104659-24-059667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651407/000110465924059667/0001104659-24-059667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651407/000110465924059667/tm2413887d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:49:54.217338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b07897abec26d37203ba3e1b65cd86bc9ce4efa9","claim":"Checkpoint Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $10.9 million, EPS $0.33 per share.","evidence_excerpt":"Net loss attributable to common stockholders for the first quarter of 2024 was $10.9 million, or $0.33 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651407/000110465924059667/0001104659-24-059667-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$10.9 million"},{"label":"EPS","value":"$0.33 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}